Alzamend Neuro, Inc.
Business
Alzamend Neuro is a clinical-stage biopharmaceutical company developing novel therapeutics for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company's pipeline includes AL001, an ionic cocrystal of lithium in Phase IIA development, and ALZN002, a cell-based immunotherapy vaccine in Phase I/IIA development, both licensed from the University of South Florida. Alzamend operates solely as a developer of drug candidates and does not manufacture or commercialize products directly; it intends to seek FDA approval and partner with established pharmaceutical companies for distribution and marketing.
Summary from 10-K filed 2025-07-22
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Research and development | 1 | 6 | 7 | 5 | 1 | |
| General and administrative | 3 | 3 | 7 | 7 | 4 | |
| Total operating expenses | 4 | 10 | 15 | — | — | |
| Loss from operations | −4 | −10 | −15 | −12 | −5 | |
| Interest expense | −18,029 | −10,101 | −7,701 | −46,524 | −142,421 | |
| Total other expense, net | −18,029 | −10,101 | −7,701 | −42,524 | −94,679 | |
| NET LOSS | −5 | −10 | −15 | −12 | −5 | |
| Dividend on preferred shares | −117,022 | — | — | — | — | |
| Deemed dividend on warrant modification issued with preferred | −473,209 | — | — | — | — | |
| NET LOSS ATTRIBUTED TO COMMON SHARES | −5 | −10 | — | — | — | |
| Basic net loss per common share | −11.32 | −132.33 | −22.89 | −0.14 | — | |
| Diluted net loss per common share | −11.32 | −132.33 | −22.89 | −0.14 | — | |
| Basic weighted average common shares outstanding | 450,799 | 74,174 | 650,126 | 89 | 73 | |
| Diluted weighted average common shares outstanding | 450,799 | 74,174 | 650,126 | 89 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Cash | 4 | 376,048 | 5 | 14 | 2 | |
| Prepaid expenses and other current assets | 228,719 | 79,194 | 447,589 | 349,723 | 983,320 | |
| TOTAL CURRENT ASSETS | 4 | 455,242 | 6 | 14 | 3 | |
| Property and equipment, net | 425,606 | 176,346 | 79,843 | 102,909 | — | |
| TOTAL ASSETS | 5 | 631,588 | 6 | 15 | 3 | |
| Accounts payable and accrued liabilities | 634,761 | 3 | — | — | — | |
| Note payable | — | 300,714 | — | — | — | |
| TOTAL LIABILITIES, ALL CURRENT | 634,761 | 3 | 3 | 1 | 899,643 | |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 778,733 and 76,444 issued and outstanding as of April 30, 2025 and 2024, respectively | 78 | 8 | 65 | 9,548 | 6,743 | |
| Additional paid-in capital | 63 | 51 | 62 | 57 | 34 | |
| Accumulated deficit | −59 | −54 | −44 | −29 | −17 | |
| TOTAL STOCKHOLDERS EQUITY (DEFICIT) | 4 | −3 | 3 | 13 | 2 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) | 5 | 631,588 | 6 | 15 | 3 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Depreciation expense | 50,740 | 50,740 | 23,066 | 3,549 | — | |
| Interest expense - debt discount | 9,286 | 714 | — | 12,770 | 124,046 | |
| Stock-based compensation to employees and consultants | 325,108 | 955,633 | 4 | 4 | 2 | |
| Prepaid expenses and other current assets | −149,525 | 368,395 | −97,866 | 633,597 | 260,791 | |
| Prepaid expenses related party | — | 247,334 | 739,918 | — | — | |
| Accounts payable and accrued liabilities | −2 | 54,937 | 2 | — | — | |
| Net cash used in operating activities | −7 | −8 | −9 | −7 | −3 | |
| Purchase of equipment | −300,000 | −147,243 | — | −106,458 | — | |
| Net cash used in investing activities | −300,000 | −147,243 | — | −106,458 | 100,915 | |
| Net proceeds from the issuance of common stock, net | 3 | 1 | — | 6 | 2 | |
| Net proceeds from the issuance of preferred stock, net | 8 | — | — | — | — | |
| Proceeds from stock option exercise | 600 | — | 200 | 2,200 | — | |
| Proceeds from the issuance of note payable | — | 300,000 | — | — | — | |
| Net proceeds from the issuance of preferred stock - related party | — | 2 | — | — | — | |
| Net cash provided by financing activities | 10 | 4 | 200 | 19 | 4 | |
| Net increase (decrease) in cash | 4 | −5 | −9 | 12 | — | |
| Conversion of Series A convertible preferred stock to common stock | 7 | — | — | — | — | |
| Conversion of Series C convertible preferred stock to common stock | 239,712 | — | — | — | — | |
| Fair value of warrants issued in connection with Series A convertible preferred stock | 2 | — | — | — | — | |
| Conversion of note payable and accrued interest into Series A convertible preferred stock | 311,356 | — | — | — | — | |
| Exchange of Series A convertible preferred stock into Series C convertible preferred stock | 977,511 | — | — | — | — | |
| Return of common stock for note receivable - related party | — | −15 | — | — | — | |
| Debt discount from issuance of note payable | — | 10,000 | — | — | — | |
| Fair value of warrants issued with preferred stock | 577,073 | — | — | — | — | |
| Fair value of warrants issued for related party payable | — | 2 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Alzamend Neuro, Inc.'s CIK number?
Alzamend Neuro, Inc.'s SEC CIK number is 0001677077 (1677077). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Alzamend Neuro, Inc.'s SEC filings?
All of Alzamend Neuro, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Alzamend Neuro, Inc. last report earnings?
Alzamend Neuro, Inc. (ALZN) most recently filed an earnings 8-K with the SEC on Jul 23, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001214659-25-010830). This is Alzamend Neuro, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Alzamend Neuro, Inc.'s most recent earnings 8-K?
Alzamend Neuro, Inc.'s latest earnings 8-K (Item 2.02) was filed Jul 23, 2025 under accession 0001214659-25-010830. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Alzamend Neuro, Inc.'s latest earnings 8-K →
Look up any company's CIK number →